Divi's Laboratories Ltd.

₹6,071

-211 (-3.4%)

DIVISLAB Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,61,407 Cr

P/E Ratio73.43

Dividend Yield0.25 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	6,281.5	Bearish
10-DMA	6,322.9	Bearish
20-DMA	6,301.25	Bearish
50-DMA	6,260.41	Bearish
100-DMA	6,376.39	Bearish
200-DMA	6,381.4	Bearish

Historical Performance

1 Year

3 Years

119.4%

5 Years

72.9%

10 Years

504.5%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	93,600	78,450	77,670	89,598	69,694
Total Expenditure	63,910	56,390	53,980	50,787	41,083
Other Income	3,520	3,390	3,450	1,159	627
Operating Profit	33,210	25,450	27,140	39,970	29,237
Interest	30	40	20	20	21
Depreciation	4,020	3,780	3,430	3,115	2,556
Profit Before Tax	29,160	21,630	23,690	36,835	26,660
Consolidated Net Profit	21,910	16,000	18,240	29,604	19,843
Adjusted EPS	83	60	69	112	75

Compounded Sales Growth

10 Years:24.6

5 Years:11.7

3 Years:0.9

TTM:3.6

Compounded Profit Growth

10 Years:20.8

5 Years:9.7

3 Years:-5.8

TTM:6.5

Stock Price CAGR

10 Years:19.6

5 Years:11.6

3 Years:30.1

TTM:8

Return on Equity

10 Years:42.4

5 Years:74.8

3 Years:68.8

last year:82.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	530	530	530	531	531
Total Reserves	1,49,160	1,35,180	1,27,140	1,16,751	92,415
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	5,000	6,110	5,570	4,365	3,639
Other Current Liabilities	4,860	4,040	3,320	3,940	3,404
Short Term Borrowings	20	---	---	---	4
Total Liabilities	1,77,170	1,59,370	1,48,630	1,46,191	1,13,869
Capital Work in Progress	10,220	7,780	2,120	4,699	7,106
Long Term Loans & Advances	3,010	1,760	970	1,337	1,726
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	11,560	7,940	7,150	15,093	7,609
Total Current Assets	1,08,770	1,01,520	97,500	96,104	67,906
Total Assets	1,77,170	1,59,370	1,48,630	1,46,191	1,13,869
Adjusted Book Value	565	512	482	442	350

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 73.43, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 30.1%, indicating sustained price appreciation.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹33210 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹93600 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1070562.6

No. of Shares: 176 (Approx)

Performance:7.1%

P/L: ₹70562.6

NIFTY Performance: 3.4%

1 day Top Gainers